goetzpartners advised tesa SE
goetzpartners advised tesa SE on the sale of tesa Labtec GmbH
goetzpartners advised
tesa SE on the
of tesa Labtec GmbH to AdhexPharma SAS
value not disclosed
Scroll down
Fortlane Partners advised tesa SE on the sale of tesa Labtec GmbH, a specialty pharmaceutical drug delivery contract development and manufacturing organization ("CDMO").
Fortlane Partners acted as exclusive M&A advisor to tesa. This transaction is Fortlane Partners' fifth transaction in the CDMO sector within only a few months.
About AdhexPharma
AdhexPharma is a pharmaceutical company specializing in the development and manufacturing of transdermal patches, oral thin films and hard-to-make dosage forms. As such AdhexPharma provides its customers with an industrial, technology expertise and know-how in the formulation, development, and commercial production of such systems. It is cGMP compliant, for both Europe and US and can handle both highly potent APIs and narcotics. Founded in 2007 for the purpose of acquiring the transdermal patch unit of Solvay in France, AdhexPharma currently manufactures five approved products representing more than 80 million units per year. AdhexPharma is headquartered in Paris and operates industrial activities in facilities located south of Dijon, France and south of Munich, Germany. AdhexPharma is part of Burgundy Ventures, an independent French industrial holding, along with its sister company Adhex.
Transaction team:
Ulrich Kinzel
Managing Director
Fabio Riva
Associate Director
David Dörsam
Associate
Simon Fischer
Analyst
Weitere TransaktionenDas könnte Sie auch interessieren...
goetzpartners advised
the insolvency administrator Michael Wilbert on the
of AbisDu Pflege GmbH to Ambiente Mobile Care GmbH
value not disclosed
goetzpartners advised
the Strüngmann family on the
of Sidroga Pharma to Uriach
value not disclosed
goetzpartners advised
Merck KGaA on the
of Allergopharma to Dermapharm Holding SE
value not disclosed
goetzpartners advised
the shareholders on the
of Vibalogics GmbH to Ampersand Capital Partners
value not disclosed
goetzpartners advised
Merck on the
of its global Consumer Health business to Procter & Gamble
3,400,000,000 €
goetzpartners advised
the shareholders of Medisorb on the
of a minority stake to CapMan
value not disclosed
goetzpartners advised
the shareholders of Dentrade on the
of the Norwegian and German operations to Modern Dental
value not disclosed
goetzpartners advised
S.P.I.F.P. on the
of Parashop to a consortium of private investors
value not disclosed
goetzpartners advised
goetzpartners advised the founder, Isatis, Quest Croissance, BNPP and the Management on the
of Vitalitec Surgical to Eurazeo PME
value not disclosed
goetzpartners advised
Jerini Bio Tools on the
to Shire
303000000,00 €